Payment overview · 2025
General Payments
$370.32
17 reported records · 4 companies
Healthcare provider profile · identity verified
Norma M. Rivera-Opio, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · HOUSTON, TX · NPI 1093767410
Verified facts
What the public records show
CMS Open Payments records show Norma M. Rivera-Opio, M.D. received $370.32 in general payments during 2025 across 17 reported records.
Novo Nordisk Inc accounted for 67.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Mounjaro, Ozempic, Rybelsus.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Prolia by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Myrbetriq by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 152 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $248.68 | 67.2% | 11 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $71.16 | 19.2% | 3 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $35.34 | 9.5% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $15.14 | 4.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $370.32 | 17 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $248.68 | 11 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $54.07 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $35.34 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $32.32 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $17.09 | 1 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $15.14 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 74 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 59 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 152 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 55 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
37 | 26 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
43 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
74 | 27 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
59 | 13 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
152 | 30 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
55 | 18 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 578 | 189 |
| Metformin Hcl | Metformin Hcl | 573 | 191 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 547 | 195 |
| Amlodipine Besylate | Amlodipine Besylate | 403 | 126 |
| Lisinopril | Lisinopril | 395 | 131 |
| Levothyroxine Sodium | Levothyroxine Sodium | 274 | 84 |
| Alendronate Sodium | Alendronate Sodium | 265 | 96 |
| Losartan Potassium | Losartan Potassium | 256 | 82 |
| Omeprazole | Omeprazole | 256 | 87 |
| Alprazolam | Alprazolam | 205 | 40 |
| Hydrochlorothiazide | Hydrochlorothiazide | 190 | 68 |
| Gabapentin | Gabapentin | 187 | 72 |
| Tramadol Hcl | Tramadol Hcl | 182 | 45 |
| Ozempic | Semaglutide | 152 | 30 |
| Furosemide | Furosemide | 151 | 45 |
| Pioglitazone Hcl | Pioglitazone Hcl | 138 | 41 |
| Tizanidine Hcl | Tizanidine Hcl | 137 | 42 |
| Enalapril Maleate | Enalapril Maleate | 132 | 37 |
| Simvastatin | Simvastatin | 132 | 43 |
| Trazodone Hcl | Trazodone Hcl | 130 | 45 |
| Metoprolol Succinate | Metoprolol Succinate | 129 | 42 |
| Tamsulosin Hcl | Tamsulosin Hcl | 128 | 52 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 125 | 35 |
| Sertraline Hcl | Sertraline Hcl | 123 | 33 |
| Clonidine Hcl | Clonidine Hcl | 119 | 55 |
| Glipizide | Glipizide | 118 | 35 |
| Metoprolol Tartrate | Metoprolol Tartrate | 118 | 39 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 114 | 15 |
| Pantoprazole Sodium | Pantoprazole Sodium | 107 | 45 |
| Clopidogrel | Clopidogrel Bisulfate | 106 | 27 |
| Ezetimibe | Ezetimibe | 105 | 37 |
| Naproxen | Naproxen | 99 | 45 |
| Tresiba Flextouch U-200 | Insulin Degludec | 98 | 28 |
| Fenofibrate | Fenofibrate Nanocrystallized | 92 | 35 |
| Meclizine Hcl | Meclizine Hcl | 92 | 45 |
| Meloxicam | Meloxicam | 88 | 44 |
| Azithromycin | Azithromycin | 85 | 73 |
| Carvedilol | Carvedilol | 84 | 36 |
| Glimepiride | Glimepiride | 81 | 26 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 80 | 18 |
| Fluticasone Propionate | Fluticasone Propionate | 78 | 38 |
| Jardiance | Empagliflozin | 74 | 27 |
| Zolpidem Tartrate | Zolpidem Tartrate | 72 | 12 |
| Montelukast Sodium | Montelukast Sodium | 66 | 31 |
| Ibuprofen | Ibuprofen | 65 | 25 |
| Vascepa | Icosapent Ethyl | 63 | 17 |
| Donepezil Hcl | Donepezil Hcl | 61 | 25 |
| Memantine Hcl | Memantine Hcl | 61 | 21 |
| Pregabalin | Pregabalin | 60 | 16 |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 59 | 19 |
| Mounjaro | Tirzepatide | 59 | 13 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 56 | 21 |
| Metolazone | Metolazone | 56 | 21 |
| Methylprednisolone | Methylprednisolone | 55 | 48 |
| Rybelsus | Semaglutide | 55 | 18 |
| Fenofibrate | Fenofibrate | 54 | 19 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 54 | 20 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 53 | 49 |
| Tresiba Flextouch U-100 | Insulin Degludec | 53 | 13 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 52 | 21 |
| Eliquis | Apixaban | 48 | 11 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 48 | 16 |
| Diclofenac Sodium | Diclofenac Sodium | 47 | 20 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 47 | 11 |
| Hydralazine Hcl | Hydralazine Hcl | 46 | 14 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 46 | 14 |
| Duloxetine Hcl | Duloxetine Hcl | 45 | 14 |
| Nifedipine Er | Nifedipine | 45 | 17 |
| Allopurinol | Allopurinol | 43 | 16 |
| Farxiga | Dapagliflozin Propanediol | 43 | 13 |
| Myrbetriq | Mirabegron | 43 | 14 |
| Januvia | Sitagliptin Phosphate | 42 | 14 |
| Escitalopram Oxalate | Escitalopram Oxalate | 39 | 15 |
| Icosapent Ethyl | Icosapent Ethyl | 39 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 37 | suppressed |
| Potassium Chloride | Potassium Chloride | 37 | 18 |
| Prolia | Denosumab | 37 | 26 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 35 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 34 | 13 |
| Finasteride | Finasteride | 33 | 11 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 32 | 18 |
| Mirtazapine | Mirtazapine | 31 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 31 | 14 |
| Dicyclomine Hcl | Dicyclomine Hcl | 30 | 14 |
| Linzess | Linaclotide | 30 | 11 |
| Lorazepam | Lorazepam | 29 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 29 | 12 |
| Benazepril Hcl | Benazepril Hcl | 28 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 28 | 11 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 27 | suppressed |
| Famotidine | Famotidine | 26 | 12 |
| Amoxicillin | Amoxicillin | 25 | suppressed |
| Latanoprost | Latanoprost | 25 | 11 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 25 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 24 | suppressed |
| Valsartan | Valsartan | 24 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 23 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 23 | 21 |
| Lactulose | Lactulose | 23 | 13 |
| Xarelto | Rivaroxaban | 23 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 22 | suppressed |
| Hydrocortisone | Hydrocortisone | 22 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 21 | suppressed |
| Novolog Flexpen | Insulin Aspart | 21 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Dutasteride | Dutasteride | 20 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 20 | suppressed |
| Risperidone | Risperidone | 20 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 19 | 11 |
| Prednisone | Prednisone | 19 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 18 | suppressed |
| Atenolol | Atenolol | 18 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 18 | suppressed |
| Cephalexin | Cephalexin | 18 | 14 |
| Clonazepam | Clonazepam | 18 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 18 | suppressed |
| Fluconazole | Fluconazole | 18 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 18 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 18 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 17 | suppressed |
| Spironolactone | Spironolactone | 17 | suppressed |
| Metronidazole | Metronidazole | 16 | 14 |
| Propranolol Hcl | Propranolol Hcl | 16 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 15 | suppressed |
| Celecoxib | Celecoxib | 15 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 15 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 15 | suppressed |
| Glipizide Er | Glipizide | 15 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 15 | suppressed |
| Ketoconazole | Ketoconazole | 14 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 14 | suppressed |
| Temazepam | Temazepam | 14 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 13 | suppressed |
| Clindamycin Phosphate | Clindamycin Phosphate | 13 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 13 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 13 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 13 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 13 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 13 | suppressed |
| Ampicillin Trihydrate | Ampicillin Trihydrate | 12 | suppressed |
| Carisoprodol | Carisoprodol | 12 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 12 | suppressed |
| Ondansetron Odt | Ondansetron | 12 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 12 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 12 | suppressed |
| Terconazole | Terconazole | 12 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 11 | suppressed |
| Famciclovir | Famciclovir | 11 | suppressed |
| Gemtesa | Vibegron | 11 | suppressed |
| Indomethacin | Indomethacin | 11 | suppressed |
| Irbesartan | Irbesartan | 11 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 11 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 11 | suppressed |
| Sucralfate | Sucralfate | 11 | suppressed |
| Telmisartan | Telmisartan | 11 | suppressed |
| Xultophy 100-3.6 | Insulin Degludec/Liraglutide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $370.32 · 17 records | Novo Nordisk Inc | JARDIANCE, KRYSTEXXA, MOUNJARO, Ozempic, Rybelsus, Veozah | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Amgen Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error